{"title":"[益气养阴方对晚期肺癌恶病质小鼠调节作用研究]。","authors":"Bin Li, Yan-xiao Li, Hong-ran Pan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To observe the effect of Yiqiyangyin formula on advanced lung cancer cachexia mice.</p><p><strong>Methods: </strong>60 C57 BL /6inbred mice( SPF) were randomly divided into normal control group, model group, Yiqiyangyin formula group,indomethacin group, and cisplatin group, with 12 mice in each group. Model group and normal control group were treated with the same amount of normal saline. Except for the normal control group, the mice of the other groups were built with Lewis lung cancer model. The changes of the level of body mass, feed consumption,serum cytokine,the expression of TNF-α and its receptor were observed.</p><p><strong>Results: </strong>After eight days of treatment, compared with cisplatin group, the levels of CEA,NSE,Pro GRP in serum,CD3+,CD4+,CD4+/ CD8+levels in serum peripheral blood and TNF-R1 expressions in tumor tissues of Yiqiyangyin formula group were increased( P < 0. 05),the contents of TNF-α and IL-6 and the expressions of TNF-α and TNF-R2 in tumor tissues of Yiqiyangyin formula group were significantly decreased( P <0. 05).</p><p><strong>Conclusion: </strong>Yiqiyangyin formula affects on advanced lung cancer cachexia, which may be related to the regulation of the immune and inflammatory cytokines expression.</p>","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Study on Regulation Effects of Yiqiyangyin Formula on Advanced Lung Cancer Cachexia Mice].\",\"authors\":\"Bin Li, Yan-xiao Li, Hong-ran Pan\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To observe the effect of Yiqiyangyin formula on advanced lung cancer cachexia mice.</p><p><strong>Methods: </strong>60 C57 BL /6inbred mice( SPF) were randomly divided into normal control group, model group, Yiqiyangyin formula group,indomethacin group, and cisplatin group, with 12 mice in each group. Model group and normal control group were treated with the same amount of normal saline. Except for the normal control group, the mice of the other groups were built with Lewis lung cancer model. The changes of the level of body mass, feed consumption,serum cytokine,the expression of TNF-α and its receptor were observed.</p><p><strong>Results: </strong>After eight days of treatment, compared with cisplatin group, the levels of CEA,NSE,Pro GRP in serum,CD3+,CD4+,CD4+/ CD8+levels in serum peripheral blood and TNF-R1 expressions in tumor tissues of Yiqiyangyin formula group were increased( P < 0. 05),the contents of TNF-α and IL-6 and the expressions of TNF-α and TNF-R2 in tumor tissues of Yiqiyangyin formula group were significantly decreased( P <0. 05).</p><p><strong>Conclusion: </strong>Yiqiyangyin formula affects on advanced lung cancer cachexia, which may be related to the regulation of the immune and inflammatory cytokines expression.</p>\",\"PeriodicalId\":15312,\"journal\":{\"name\":\"中药材\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中药材\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Study on Regulation Effects of Yiqiyangyin Formula on Advanced Lung Cancer Cachexia Mice].
Objective: To observe the effect of Yiqiyangyin formula on advanced lung cancer cachexia mice.
Methods: 60 C57 BL /6inbred mice( SPF) were randomly divided into normal control group, model group, Yiqiyangyin formula group,indomethacin group, and cisplatin group, with 12 mice in each group. Model group and normal control group were treated with the same amount of normal saline. Except for the normal control group, the mice of the other groups were built with Lewis lung cancer model. The changes of the level of body mass, feed consumption,serum cytokine,the expression of TNF-α and its receptor were observed.
Results: After eight days of treatment, compared with cisplatin group, the levels of CEA,NSE,Pro GRP in serum,CD3+,CD4+,CD4+/ CD8+levels in serum peripheral blood and TNF-R1 expressions in tumor tissues of Yiqiyangyin formula group were increased( P < 0. 05),the contents of TNF-α and IL-6 and the expressions of TNF-α and TNF-R2 in tumor tissues of Yiqiyangyin formula group were significantly decreased( P <0. 05).
Conclusion: Yiqiyangyin formula affects on advanced lung cancer cachexia, which may be related to the regulation of the immune and inflammatory cytokines expression.
期刊介绍：
"Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
